In the present study, we analyzed the eŠect of recombinant human granulocyte colony stimulating factor (rhG CSF) on neutrophil counts in cancer patients undergoing chemotherapy using a previously developed pharmacokinetic/ pharmacodynamic model. 7) The time proˆles of neutrophil counts in blood after repeated administration of rhG CSF to lung cancer patients undergoing chemotherapy could be analyzed by this model by considering the inhibition of neutrophil production by antineoplastic drugs. Although deviation was observed between the predicted and observed neutrophil counts in ovarian cancer patients, it may be possible to use this model for determining a rational dosage regimen of rhG CSF for patients undergoing chemotherapy.
INTRODUCTION
Recombinant human granulocyte colony stimulating factor (rhG CSF) is widely used for the treatment of neutropenia associated with cancer chemotherapy, leukemia and aplastic anemia. [2] [3] [4] [5] Although its mechanism for disposition has been studied extensively in rodents, 6 ) the establishment of a pharmacokinetic/pharmacodynamic model is needed to predict the pharmacological eŠect of rhG CSF in humans. We developed such a model in our previous study and showed that the model enables prediction of increase in the number of neutrophils after administration of rhG CSF to healthy volunteers. 7) In this model, the pharmacological action of rhG CSF was assumed to be proportional to the amount of a ternary complex composed of rhG CSF, its receptor and the putative eŠector molecule. 7) The GTP binding protein may be responsible for this putative eŠec-tor molecule, since the binding of rhG CSF to the receptor induces the activation of adenylate cyclase through the GTP binding protein. By using this model, we were able to obtain time proˆles of the increase in the number of neutrophils after administration of rhG CSF. 7) We also provided a theoretical background for the fact that the increase in neutrophil count after s.c. administration is larger than that after i.v. administration of the same dose. 7) However, for rhG CSF treatment of patients who have received antineoplastic drugs, it is essential to consider the decrease in the number of neutrophils and their precursor (C CFU) in analyzing the eŠect of rhG CSF. In the present study, we reˆned our previous model by considering the inhibition of neutrophil production caused by exposure to antineoplastic drugs in order to establish a rational regimen for rhG CSF treatment.
METHODS

Patients' Backgrounds
Time proˆles of neutrophil counts in 3 female patients with lung cancer and 3 female patients with ovarian cancer were analyzed in the present study. Two of the lung cancer patients received the i.v. administration of paclitaxel (200 mg/m 2 ) and carboplatin, whereas one of the lung cancer patients received the i.v. administration of paclitaxel (60 mg/m 2 ) and cisplatin (80 mg/m 2 ). The dose of carboplatin was determined so that the AUC of this drug will be 6 and 5mg/ml･min for the ovarian and lung cancer patients, respectively, according to the Calvert's equation. 8) Two of the ovarian cancer patients received the i.v. administration of paclitaxel (100 mg/m 2 ), cisplatin (75 mg/m 2 ) and adriamycin (40 mg/m 2 ), whereas one of the ovarian The pharmacokinetic/pharmacodynamic model used for the analysis of neutrophil counts after administration of rhG CSF was a modiˆcation of the previously described model (Fig. 1) . 7) In this model, it is assumed that the speciˆc binding of rhG CSF to the receptor on C CFU induces the activation of adenylate cyclase through the GTP binding protein, leading to the proliferation of neutrophils. The equilibrium of rhG CSF [D] (pM), receptor [R] (sites/cell) and eŠector [E] (sites/cell) in a steady state is given by Eqs. (1) and (2). 
Assuming that the pharmacological eŠect of rhG CSF is in proportion to [DRE], the normalized relative eŠect of rhG CSF is given by Eq. (7).
is the rate constant for the generation of neutrophils from C CFU, which is the precursor of neutrophils, and K s max (h -1 ) is the maximum value of K s . N C CFU, SS (cells/ml) represents the number of C CFU in a steady state.
In the absence of rhG CSF, the rate of generation of neutrophils is assumed to be constant with the rate of K･N C CFU (cells/ml/h), and the decomposition of blood neutrophils follows aˆrst order elimination process at the rate constant of K c (h -1 ). Based on this assumption, the neutrophil count in blood at time t ( N(cells/ml)) is given by Eq. (8) .
dN/dt＝K･N C CFU, SS -K c ･N (8) The constant value of N 0 (cells/ml), which represents the net neutrophil count in blood should, be maintained (Eq. (9)):
N 0 ＝K･N C CFU, SS /K c (9) In the presence of rhG CSF, the rate of generation of neutrophils is increased with the rate constant of K s (hr -1 ) as follows:
dN/dt＝K･N C CFU, ss ＋K s ･N C CFU, SS -K c ･N (10) Then, N 0 (cells/ml) is mean neutrophil count in blood for patients in the evening of the day before administration of an antineoplastic drug.
dN/dt＝N 0 ･K c ＋K s ･N C CFU, SS -K c ･N (11) After administration of an antineoplastic drug, it is assumed that N C CFU is given by
＋exp (-K a  ･t )) (12) and, consequently, the number of neutrophils is given by Eq. (13):
(12) and (13), K a (hr -1 ) represents theˆrst order rate constant for the decrease in the neutrophil number induced by antineoplastic drugs, and K e : (hr -1 ) represents theˆrst order rate constant for the recovery of the neutrophil number. In general, the number of neutrophils after repeated administration of rhG CSF for n(n＞2) times is given by Eq. (14):
Time proˆles of neutrophil counts wereˆtted to Eqs. (13) and (14) to obtain K e and K a values using a program reported previously. 9) In theˆtting, K s value was zero prior to the administration of rhG CSF. The initial value of N n was set to be equal to the neutrophil number calculated for the time just prior to n th administration of rhG CSF. The values of K s ･ N C CFU, SS and K c wereˆxed to 2.12 (cell/ml/h) 0.107 (hr -1 ), respectively, according to our previous report. 7) 
RESULTS
Time Proˆles of Neutrophil Counts in Patients
Time proˆles of neutrophil counts in patients with lung cancer and ovarian cancer are shown in Figs. 2  and 3 , respectively. These proˆles wereˆtted to Eq. Time proˆles of neutrophil counts were also simulated by assuming that the neutrophil number before initiation of the administration is 3×10 3 and 4.5×10 3 
DISCUSSION
Neutropenia is one of the major obstacles for continuation of tumor therapy with antineoplastic drugs. 10, 11) After chemotherapy, rhG CSF is widely used to increase the number of neutrophils. An accurate pharmacokinetic/pharmacodynamic model of rhG CSF is needed for determining a rational dosage regimen of rhG CSF. In the present study, we incorporated decrease in the number of neutrophils in our previously described pharmacokinetic/pharmacodynamic model of rhG CSF. 7) In the present analysis, we assumed that the number of neutrophils after administration of antineoplastic drugs is given by Eq. (11). This assumption is based on the fact that the number of neutrophils is reduced after administration of antineoplastic drugs and later recovers to the normal level. 12, 13) In a strict manner, such time proˆles for the neutrophil count should be described by considering the pharmacological eŠect of antineoplastic drugs on C CFU, along with the rate constants for the proliferation and diŠerentiation of C CFU and that for the turnover of neutrophils as described previously. 14)-16) From such a point of view, the values of K a  and K e should depend on the kind of antineoplastic drugs and their plasma concentration proˆles. 14)-16) Under conditions in which proliferation and diŠeren-tiation of C CFU are almost completely inhibited by antineoplastic drugs, the K a value should represent the rate constant for the turnover of neutrophils. Since antineoplastic drugs are administered at their maximum tolerated doses, it is plausible that the calculated K a values is consistent with the turnover rate of neutrophils.
By using the present model, the time proˆles of neutrophil counts could be analyzed for patients with lung cancer, whereas deviation was observed between the predicted and observed neutrophil counts in ovarian cancer patients (Figs. 2 and 3 ). It may be di‹cult to analyze the neutrophil number if the damage of progenitor cells induced by the chemotherapy is extensive. For these patients, we also simulated the neutrophil counts assuming that they did not receive rhG CSF. As shown by the dotted lines in Figs. 2 and 3 , it was demonstrated that the recovery of neutrophil counts is greatly delayed without the administration of rhG CSF.
Although results of analysis using many patients are required for validation of this model, it may be possible to use this model in order to determine a rational dosage regimen of rhG CSF. For this purpose, we performed simulation of neutrophil counts after administration of antineoplastic drugs and rhG CSF (Figs. 4 and 5 ). Assuming that a patient had 4.5×10 3 neutrophils/ml blood before the administration of antineoplastic drugs, the time proˆles of neutrophil count was simulated as a function of K a value (Fig.  5) . In order to maintain a minimal neutrophil count in blood (0.5×10 3 neutrophils/ml blood), the patient should receive rhG CSF 9 days after the initiation of chemotherapy if the K a value is 0.015 hr -1 , which was determined for patients undergoing chemotherapy for lung cancer (Fig. 3) . However, these patients should receive rhG CSF 6 days after initiation of chemotherapy if the K a value is 0.02 hr -1 , which was calculated for patients undergoing chemotherapy for ovarian cancer (Fig. 2) . In addition, if it is assumed that the patient has 3.0×10 3 neutrophils/ml blood before the administration of antineoplastic drugs and that the K a value is 0.015 hr -1 , rhG CSF should be administered 7 days after initiation of the chemotherapy, in order to maintain the minimal level of neutrophils (Fig. 4) . In contrast, rhG CSF should be administered 4 days after the initiation of chemotherapy if the K a value is 0.02 hr -1 (Fig. 2) . It is suggested that we can provide a rational dosage design of rhG CSF by analyzing the decline of neutrophil count in blood after initiation of chemotherapy.
In the present study, we found that the eŠect of rhG CSF on neutrophil count in patients undergoing chemotherapy can be analyzed by using the pharmacokinetic/pharmacodynamic model. Although results of analysis using many patients is required, it may be possible to use this model for the purpose of determining the rational regimen of rhG CSF for patients undergoing chemotherapy.
